287 related articles for article (PubMed ID: 37217603)
1. The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era.
Montero E; Isenberg JS
Cancer Immunol Immunother; 2023 Sep; 72(9):2879-2888. PubMed ID: 37217603
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin-1, CD47, and SIRPα display cell-specific molecular signatures in human islets and pancreata.
Erdem N; Chen KT; Qi M; Zhao Y; Wu X; Garcia I; Ku HT; Montero E; Al-Abdullah IH; Kandeel F; Roep BO; Isenberg JS
Am J Physiol Endocrinol Metab; 2023 Apr; 324(4):E347-E357. PubMed ID: 36791324
[TBL] [Abstract][Full Text] [Related]
3. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
4. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
6. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
7. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
8. TSP1-CD47-SIRPα signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium.
Liu Y; Li M; Wei C; Tang L; Sheng Y; Liu Y; Li D; Ding D; Qiu J; Zhu X
Am J Reprod Immunol; 2020 Jun; 83(6):e13236. PubMed ID: 32196807
[TBL] [Abstract][Full Text] [Related]
9. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
11. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
12. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J
PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567
[TBL] [Abstract][Full Text] [Related]
13. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
14. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
Bouwstra R; van Meerten T; Bremer E
Clin Transl Med; 2022 Aug; 12(8):e943. PubMed ID: 35908284
[TBL] [Abstract][Full Text] [Related]
15. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells.
Seiffert M; Brossart P; Cant C; Cella M; Colonna M; Brugger W; Kanz L; Ullrich A; Bühring HJ
Blood; 2001 May; 97(9):2741-9. PubMed ID: 11313266
[TBL] [Abstract][Full Text] [Related]
16. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
17. Macrophages show higher levels of engulfment after disruption of
Hayes BH; Tsai RK; Dooling LJ; Kadu S; Lee JY; Pantano D; Rodriguez PL; Subramanian S; Shin JW; Discher DE
J Cell Sci; 2020 Mar; 133(5):. PubMed ID: 31964705
[TBL] [Abstract][Full Text] [Related]
18. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint.
Wu ZH; Li N; Mei XF; Chen J; Wang XZ; Guo TT; Chen G; Nie L; Chen Y; Jiang MZ; Wang JT; Wang HB
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256517
[TBL] [Abstract][Full Text] [Related]
20. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
